{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:27Z","timestamp":1790057067026,"version":"4.0.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011482","name":"Yantai Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Metastatic triple-negative breast cancer (mTNBC) is an aggressive malignancy with limited targeted therapeutic alternatives and dismal long-term prognosis. Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate (ADC) conjugated to the topoisomerase I inhibitor SN-38. SG has demonstrated robust anti-tumor activity across multiple clinical trials for mTNBC. We present a hypothesis-generating case report of a 50-year-old female patient with stage III triple-negative breast cancer (TNBC) who received curative-intent surgery followed by adjuvant multimodal therapy. Fourteen months after completing adjuvant treatment, the patient developed bone-only recurrence and received local bone radiotherapy plus first-line albumin-bound paclitaxel plus carboplatin chemotherapy, followed by capecitabine maintenance until 25 April 2023. Upon successive systemic disease progression, the patient sequentially received second-line toripalimab plus gemcitabine and third-line toripalimab plus eribulin through November 2023. Cervical lymph node biopsy confirmed metastatic TNBC with negative BRCA germline status and PD-L1 tumor proportion score (TPS) &amp;lt; 1%. Per international and domestic clinical guidelines, single-agent SG (10\u00a0mg\/kg) was initiated as fourth-line therapy. During SG monotherapy, recurrent symptomatic malignant pleural effusion developed, and oral anlotinib 10\u00a0mg (days 1\u201314 every 21-day cycle) was added to the treatment regimen starting 18 July 2024. As of 4 February 2025, the patient completed 7 cycles of SG monotherapy and 9 cycles of sequential SG plus anlotinib combination treatment. Clinically, no recurrent pleural effusion was observed after anlotinib initiation; measurable pulmonary, hepatic, and cervical nodal metastases exhibited sustained shrinkage alongside declining serum tumor markers, yielding a 12-month progression-free survival (PFS). Grade 1\u20132 treatment-emergent adverse events included leukopenia, neutropenia, diarrhea, and fatigue, all manageable with supportive care. To our knowledge, this is the first descriptive case documenting sustained disease control following SG plus anlotinib combination in heavily pretreated mTNBC complicated by recurrent malignant pleural effusion. It should also be noted that although the timing of clinical symptom improvement coincided with the initiation of anlotinib, this single case cannot differentiate whether the clinical benefit observed derived from the potential synergistic effect of the two agents or the monotherapeutic effect of anlotinib alone. Without validation from phase II\/III prospective clinical trials, this case only generates a preliminary hypothesis that SG combined with anlotinib may represent a potential salvage therapeutic strategy for heavily pretreated advanced TNBC patients complicated by refractory malignant pleural effusion or localized progression under single-agent SG. Further prospective clinical research is required to verify the synergistic activity of this regimen.<\/jats:p>","DOI":"10.3389\/fphar.2026.1800856","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:04Z","timestamp":1790055544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab govitecan combined with anlotinib in metastatic triple negative breast cancer patient with repeated pleural effusion: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Congcong","family":"Wang","sequence":"first","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Xu","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Han","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Qu","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Liu","sequence":"additional","affiliation":[{"name":"Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of Anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast Cancer[J\/OL]","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast Cancer[J\/OL]","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J\/OL]","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet London, Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.48048\/tis.2025.9490","article-title":"Challenges and strategies to enhance drug efficacy of the approved drugs for chemoresistant triple-negative breast cancer: a narrative Review[J\/OL]","volume":"22","author":"Kumari","year":"2025","journal-title":"Trends Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1[J\/OL]","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/1759-7714.14176","article-title":"Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: subgroup analysis from a randomized, multicenter, phase II study[J\/OL]","volume":"12","author":"Liu","year":"2021","journal-title":"Thorac. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast Cancer[J\/OL]","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation[J\/OL]","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid decrease in delivery of chemotherapy to tumors after Anti-VEGF therapy: implications for scheduling of anti-angiogenic Drugs[J\/OL]","volume":"21","author":"VAN Der Veldt","year":"2012","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J\/OL]","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.2147\/CMAR.S252181","article-title":"Anlotinib suppresses colorectal cancer proliferation and angiogenesis via inhibition of AKT\/ERK signaling Cascade[J\/OL]","volume":"12","author":"Yang","year":"2020","journal-title":"Cancer Manag. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:05Z","timestamp":1790055545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":11,"alternative-id":["10.3389\/fphar.2026.1800856"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1800856","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1800856"}}